Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects

Metabolism: Clinical and Experimental

Volumn 58, Issue 11, 2009, Pages 1536-1542

  Otokozawa, Seiko ^a   Ai, Masumi ^a   Diffenderfer, Margaret R ^a   Asztalos, Bela F ^a   Tanaka, Akira ^b   Lamon Fava, Stefania ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b KAGAWA NUTRITION UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B48; CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REPRODUCIBILITY; BLOOD; BODY MASS; MIDDLE AGED; PHYSIOLOGY; REFERENCE VALUE;

APOLIPOPROTEIN B-48; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; REFERENCE VALUES; TRIGLYCERIDES;

EID: 70449715639     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.04.040     Document Type: Article

References (34)

1. Schaefer E.J. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 75 (2002) 191-212
2. Schaefer E.J., Gregg R.E., Ghiselli G., Forte T.M., and Ordovas J.M. Familial apolipoprotein E deficiency. J Clin Invest 78 (1986) 1206-1219
3. Proctor S.D., Vine D.F., and Mamo J.C. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 13 (2002) 461-470
4. Kane J.P., Hardman D.A., and Paulus H.E. Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc Natl Acad Sci USA 77 (1980) 2465-2469
5. Cohn J.S., McNamara J.R., Cohn S.D., Ordovas J.M., and Schaefer E.J. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 29 (1988) 469-479
6. Cohn J.S., McNamara J.R., Cohn S.D., Ordovas J.M., and Schaefer E.J. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 29 (1988) 925-935
7. Cohn J.S., McNamara J.R., Krasinski S.D., Russell R.M., and Schaefer E.J. Role of triglyceride-rich lipoproteins from the liver and intestine in the etiology of postprandial peaks in plasma triglyceride concentration. Metabolism 38 (1989) 484-490
8. Cohn J.S., Johnson E.J., Millar J.S., Cohn S.D., Milne R.W., Marcel Y.L., et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 34 (1993) 2033-2040
9. Krasinski S.D., Cohn J.S., Russell R.M., and Schaefer E.J. Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl esters as markers for intestinally-derived chylomicrons and their remnants. Metabolism 39 (1990) 357-365
10. Lemieux S., Fontani R., Uffelman K., Lewis G., and Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins. J Lipid Res 39 (1998) 1964-1971
11. Campos E., Kotite L., Blanche P., Mitsugi Y., Frost P.H., Masharani U., et al. Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human plasma. J Lipid Res 43 (2002) 365-374
12. Smith D., Watts G.F., Dana-Stewart C.A., and Mano J.C.L. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 29 (1999) 204-209
13. Sasaki N., Uchida Y., Ohashi K., Hibuse T., Saika Y., Tomari Y., et al. Measurement of fasting serum apoB48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 44 (2003) 1256-1262
14. Uchida Y., Kurano Y., and Ito S. Establishment of monoclonal antibody against human apo B-48 and measurement of apo B-48 in serum by ELISA method. Clin Lab Anal 12 (1998) 89-292
15. Kinoshita M., Kojima M., Matsushima T., and Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 351 (2005) 115-120
16. Lamon-Fava S., Diffenderfer M.R., Barrett P.H.R., Buchsbaum A., Matthan N.R., Lichtenstein A.H., et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-1 metabolism. J Lipid Res 48 (2007) 1746-1753
17. Sugiuchi H., Irie T., Uji Y., Ueno T., Chaen T., Uekama K., et al. Homogeneous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer and α-cyclodextrin sulfate. Clin Chem 44 (1998) 522-531
18. Sugiuchi H., Uji Y., Okabe H., Irie T., Uekama K., Kayahara N., et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated α-cyclodextrin. Clin Chem 41 (1995) 717-723
19. Miyauchi K., Kayahara N., Ishigami M., Kuwata H., Mori H., Sugiuchi H., et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem 53 (2007) 2128-2135
20. Miyauchi K., Kuwata H., Sugiuhi H., and Irie T. Development of a direct remnant lipoprotein cholesterol assay using detergent. Clin Chem 34 (2005) 325-331
21. Sakai N., Uchida Y., Ohashi K., Hibuse T., Saika Y., Tomari Y., et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 44 (2003) 1256-1262
22. Jackson K.G., and Williams C.M. Apolipoprotein B-48: comparison of fasting concentrations measured in normolipidemic individuals using SDS-PAGE, immunoblotting and ELISA. Atherosclerosis 176 (2004) 207-217
23. Campos H., Khoo C., and Sacks F.M. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic subjects. Atherosclerosis 181 (2005) 345-351
24. Schaefer E.J., Audelin M.C., McNamara J.R., Shan P.K., Tayler T., Daly J.A., et al. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol 88 (2001) 1129-1133
25. Nakada Y., Kurosawa H., Tohyama J., Inoue Y., and Ikewaki K. Increased remnant lipoprotein in patients with coronary artery disease-evaluation utilizing newly developed remnant assay, remnant lipoprotein cholesterol homogeneous assay (RemL-C). J Atheroscler Thromb 14 (2007) 56-64
26. Karpe F., Steiner G., Uffelman K., Olivecrona T., and Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106 (1994) 83-97
27. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W.F., Ordovas J.M., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 154 (2001) 229-236
28. Welty F.K., Lichtenstein A.H., Barrett P.H.R., Dolnikowski G.G., and Schaefer E.J. Interrelationships between human apolipoprotein A-I and apolipoprotein B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 24 (2004) 1703-1707
29. Batista M.C., Welty F.K., Diffenderfer M.R., Samak M.J., Schaefer E.J., Lamon-Fava S., et al. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism 53 (2004) 1255-1261
30. Lamon-Fava S., Diffenderfer M.R., Barrett P.H., Buchsbaum A., Nyaku M., Horvath K.V., et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins. Artherioscler Thromb Vasc Biol (2008)
31. Castro C.M., Erkelens D.W., Kock L.A., and De Bruin T.W. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest 24 (1994) 669-678
32. Battula S.B., Fitzsimmons O., Moreno S., Owens D., Collins P., Johnson A., et al. Postprandial apolipoprotein B-48- and apoB-100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?. Metabolism 49 (2000) 1049-1054
33. Dane-Stewart C.A., Watts G.F., Pal S., Chen D., Thompson P., Hung J., et al. Effect of atorvastatin on apolipoprotein B-48 metabolism and low density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism 52 (2003) 1279-1286
34. Verseyden C., Meijssen S., and Cabezas M.C. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B-48 and B-100 in large, triglyceride- rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 89 (2004) 5021-5029